

S4 Table. Neutralizing antibody levels against SARS-CoV-2 strains in the vaccinated cancer cohorts

	Wild-type virus	Delta variant	Omicron variant
2nd, Ca-mRNA ^{a)}	278 (213-363)	133 (100-177)	12 (9-16)
2nd, Ca-AdV ^{b)}	256 (350-456)	114 (77-169)	13 (10-16)
3rd, Ca-mRNA ^{c)}	582 (144-456)	397 (219-719)	36 (15-88)
3rd, Ca-AdV ^{d)}	513 (311-845)	272 (144-514)	14 (8-25)

Values are presented as geometric mean titer (95% confidence interval). SARS-CoV-2, severe acute respiratory syndrome coronavirus 2. ^{a)}Cancer patients who received two doses of mRNA vaccines (either BNT162b2 or mRNA-1273), ^{b)}Cancer patients who received two doses of adenovirus vector vaccine (AZD1222), ^{c)}Cancer patients who received three doses of mRNA vaccine (either BNT162b2 or mRNA-1273), ^{d)}Cancer patients who received two doses of adenovirus vector vaccine (AZD1222) followed with mRNA vaccines (either BNT162b2 or mRNA-1273).